Obermatt

Masimo

NSQ:MASI · US5747951003
Health Care Equipment & SuppliesLarge

360

44
Medium confidence — indicative
EV / EBIT24
Price / Owner Earnings7
Owner Earnings Yield30
Dividend Yield1
Price/Sales54
EV / Gross Profit13
Price/Book11
Return on Capital89
Cash Return on Capital62
Return on Equity91
EBIT Margin78
Gross Profitability91
Cash Conversion88
Accruals97
Owner Earnings Margin36
Sales growth46
Profit Growth91
Long-Term EPS Growth78
Reinvestment72
Price momentum28
Debt load33
Refinancing91
Debt Payback38
Liquidity97
Analyst ratings9
Opinion Changes84
Price Target Upside6
Market mood66
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Masimo clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Equipment & Supplies
SizeLarge
TypePrivate Company
ExchangeNASDAQGS
Founded1989
Employees2,205
Websitemasimo.com
ISINUS5747951003
Last UpdateApr 2, 2026
Themes
Process AutomationRespiratoryBiomedical EngineeringHealth DiagnosticsSleep TechnologySensorsNeurologyDetectors, Sensors and MemsWellness and RecoveryWearablesBiotechnologyManufacturingMedical Device

Description

Masimo Corporation, a global medical technology company, develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo Hospital Automation and…

Analysis

Beloved champion

Masimo Corporation is a beloved champion: its quality is genuine, and the market already prices it as exceptional.

The price is expensive. You pay 92.0× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 27% yearly growth; analysts expect 17%. The gap between price and consensus is worth watching: demanding expectations.

The trajectory is mixed and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
74
2023202420252026

All-time high

74

Jun 2026

All-time low

1

Jan 2024

Average rank

46

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
54
38
56
23
Price/Earnings
5
20
19
21
Price/Book
11
37
44
43
Dividend Yield
1
1
1
1
Value (overall)
1
17
47
30

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Masimo with its peers
Quest Diagnostics
NYQ:DGX
35
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Adaptive Biotechnologies
NSQ:ADPT
20
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Pacific Biosciences of California
NSQ:PACB
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Comtech
NSQ:CMTL
59
CountryUSA
IndustryCommunications Equipment
SizeSmall
Full Stock Analysis →
Labcorp
NYQ:LH
40
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Ambarella
NSQ:AMBA
19
CountryUSA
IndustrySemiconductors & Semiconductor Equipment
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →